Intercytex Completes Phase 1 Trial for Hair Multiplication
April 6, 2005
Intercytex is a company based in the UK that has developed a technique for taking hair dermal papilla cells from
healthy hair and culturing them to produce more cells. This is hair multiplication. They have
named their technique ICX-TRC and intend to go through the necessary processes and tests to make it available
as a future treatment for male pattern baldness and female pattern baldness.
They have announced recently that a Phase 1 clinical trial for safety has been completed in seven volunteers at
a transplant center in the UK. Five out of the seven volunteers saw increased numbers of hair.
Intercytex intends to start a multi-center Phase II clinical trial in a larger number of individuals with male
pattern baldness in the first half of 2006 in the UK and the US. This will be followed by a Phase III trial for both
male pattern and female pattern baldness, currently planned for 2007.
Here is the announcement from Intercytex: ICX-TRC
This is great news for the advancement of hair loss treatment. Hopefully the Phase II and III trials will yield positive
results. The benefits of a safe and effective hair multiplication technique will include not having to relocate existing hair
from the non-balding areas of the scalp, thereby eliminating the donor scar from a conventional hair transplant, and also having
an abundance of supply. Being able to produce cultured hair cells could mean that hair lines can be restored beyond what would
be prudent in a conventional hair transplant as well as improving the overall density that can be achieved.
Return to News and Interviews.
|
